Qiagen N.V.
Qiagen N.V. (QGEN) Financial Performance & Income Statement Overview
Explore the financials of Qiagen N.V. (QGEN), including yearly and quarterly data on income, cash flow, and balance sheets.
Qiagen N.V. (QGEN) Income Statement & Financial Overview
Analyze Qiagen N.V.’s QGEN earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $483.46M | $521.20M | $501.87M | $496.35M |
| Cost of Revenue | $174.78M | $171.40M | $193.56M | $461.58M |
| Gross Profit | $308.68M | $349.80M | $308.31M | $34.76M |
| Gross Profit Ratio | $0.64 | $0.67 | $0.61 | $0.07 |
| R&D Expenses | $43.78M | $48.60M | $44.45M | $49.10M |
| SG&A Expenses | $137.94M | $141.71M | $140.66M | $143.30M |
| Operating Expenses | $193.33M | $230.70M | $196.20M | $278.41M |
| Total Costs & Expenses | $368.11M | $402.10M | $389.77M | $724.78M |
| Interest Income | $15.39M | $15.09M | $18.25M | $16.91M |
| Interest Expense | $7.29M | $11.14M | $11.48M | $10.92M |
| Depreciation & Amortization | $43.91M | $45.55M | $49.99M | $53.39M |
| EBITDA | $170.75M | $182.55M | $177.93M | -$159.14M |
| EBITDA Ratio | $0.35 | $0.35 | $0.35 | -$0.32 |
| Operating Income | $115.35M | $119.10M | $112.10M | -$228.44M |
| Operating Income Ratio | $0.24 | $0.23 | $0.22 | -$0.46 |
| Other Income/Expenses (Net) | $4.20M | $6.75M | $4.35M | $4.99M |
| Income Before Tax | $119.55M | $125.85M | $116.46M | -$223.45M |
| Income Before Tax Ratio | $0.25 | $0.24 | $0.23 | -$0.45 |
| Income Tax Expense | $28.79M | $37.53M | $18.40M | -$39.99M |
| Net Income | $90.76M | $88.32M | $98.06M | -$183.46M |
| Net Income Ratio | $0.19 | $0.17 | $0.20 | -$0.37 |
| EPS | $0.42 | $0.41 | $0.44 | -$0.83 |
| Diluted EPS | $0.41 | $0.40 | $0.44 | -$0.83 |
| Weighted Avg Shares Outstanding | $218.38M | $216.12M | $222.31M | $221.99M |
| Weighted Avg Shares Outstanding (Diluted) | $220.19M | $218.02M | $224.03M | $221.99M |
Financial performance has remained strong, with revenue growing from $496.35M in Q2 2024 to $483.46M in Q1 2025. Gross profit continued to perform well, with margins at 64% in the latest quarter. Operating income reached $115.35M in Q1 2025, holding a steady 24% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $170.75M. Net income rose to $90.76M, keeping EPS at $0.42. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan